Elbasvir and grazoprevir, new direct-acting antiviral agents with activity disease psychosis. Brivaracetam, an antiepileptic drug that is an analog of levetiracetam, is indicated as adjunctive therapy in treatment of partial-onset seizures. Reslizumab, a monoclonal antibody that acts as an interleukin-5 antagonist, is indicated as add-on maintenance treatment of patients with severe asthma and an eosinophilic phenotype. Ixekizumab, an interleukin-17A antagonist, is administered subcutaneously for treatment of moderate to severe plaque psoriasis. Patiromer sorbitex calcium, which binds with potassium in the gastrointestinal tract, is indicated in treatment of hyperkalemia.
After participating in this activity, the pharmacist will be able to:
- Identify new FDA-approved therapeutic agents marketed in 2016, and explain their appropriate use.
- Identify the agents’ indications and mechanisms of action.
- Identify the agents’ most important adverse events and other risks.
- State route of administration for each new agent and the most important dosage and administration considerations.
- Compare the new agents with older medications to which they are most similar in properties and use, and identify their most important advantages and disadvantages.
Activity type: Knowledge-based
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
To obtain 2.0 contact hours of continuing pharmacy education credit (0.2 CEUs) for completing "New Therapeutic Agents Marketed in 2016: Part 1," complete the CPE examination and evaluation questions. Credit will be awarded upon achieving a passing grade of 70% or better. Please visit CPE Monitor for your statement of credit/transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. Exam questions may not appear in the same order as printed.
The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the test. Individuals completing this activity by September 1, 2019 can receive credit.
Initial release date: September 1, 2016
Expiration date: September 1, 2019
ACPE Universal Activity Numbers: 0202-0000-16-190-H01-P and 0202-0000-16-190-H01-T.
Mark S. Johnson, PharmD, BCPS
Professor and Vice Chair, Department of Pharmacy Practice
Director of Postgraduate Education
Bernard J. Dunn School of Pharmacy
Mark S. Johnson, PharmD, BCPS, declares that he and his spouse hold stock in Merck & Co. Daniel A. Hussar, PhD, FAPhA; Eric F. Hussar, MD; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria.. For complete staff disclosures please see the APhA Accreditation Information section at www.pharmacist.com/apha-disclosures.
"New Therapeutic Agents Marketed in 2016: Part 1” is a home-study continuing education activity for pharmacists and pharmacy technicians developed by the American Pharmacists Association.
There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-16-190-H01-P||0.2 CEUs||September 01, 2016 - September 01, 2019|
|ACPE# 0202-0000-16-190-H01-T||0.2 CEUs||September 01, 2016 - September 01, 2019|